Early serum hepatitis B virus large surface protein level: A stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B

Zhu, Xuejuan; Gong, Qiming; Yu, Demin; Zhang, Donghua; Gu, Leilei; Han, Yue; Chen, Jia; Zhang, Yan; Zhang, Xinxin

doi:10.1016/j.jcv.2013.04.003

Cited by 15 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to the results of Wang et al and Zhu et al, we found that HBs levels correlated with those of other viral markers, but not with ALT levels. While a weak correlation between LHBs and HBsAg ( r s = 0.46‐0.59) was reported by these authors, the correlation between HBs proteins (including LHBs) and HBsAg in our study was particularly high ( r s = 0.94‐0.97).…”

Section: Discussionsupporting

confidence: 91%

“…While a weak correlation between LHBs and HBsAg ( r s = 0.46‐0.59) was reported by these authors, the correlation between HBs proteins (including LHBs) and HBsAg in our study was particularly high ( r s = 0.94‐0.97). The divergence may be a result of suboptimal HBsAg quantitation, because Zhu et al found a better correlation of HBV DNA to LHBs than to HBsAg. Furthermore, the LHBs levels measured in our study were approximately 10‐20 times higher than those found by Zhu et al Such large divergences highlight the need for international standardization, as exists for total HBsAg.…”

Section: Discussionmentioning

confidence: 99%

“…The divergence may be a result of suboptimal HBsAg quantitation, because Zhu et al found a better correlation of HBV DNA to LHBs than to HBsAg. Furthermore, the LHBs levels measured in our study were approximately 10‐20 times higher than those found by Zhu et al Such large divergences highlight the need for international standardization, as exists for total HBsAg. Consistent with Zhu et al, we showed that absolute biomarker levels are more predictive of treatment response than change from baseline levels.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Quantitation of large, middle and small hepatitis B surface proteins in HBeAg‐positive patients treated with peginterferon alfa‐2a

Rinker

Bremer

Schröder

et al. 2019

Liver International

View full text Add to dashboard Cite

Abbreviations: aa, amino acid; ALT, alanine aminotransferase; AUC, area under the curve; CHB, chronic hepatitis B; CI, confidence interval; ELISA, enzyme-linked immunosorbent assay;HBeAg, hepatitis B e antigen; HBs, hepatitis B surface (protein); HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; LAM, lamivudine; LLOQ, lower limit of quantification;PegIFN, peginterferon alfa-2a; qHBsAg, quantitative hepatitis B surface antigen; ROC, receiver operating characteristic; SC, seroconversion; SHBs/MHBs/LHBs, small/middle/large hepatitis B surface (protein); SVP, subviral particle. Abstract Background & Aims: Hepatitis B virus (HBV) contains three viral surface proteins, large, middle and small hepatitis B surface protein (LHBs, MHBs, SHBs). Proportions of LHBs and MHBs are lower in patients with inactive vs active chronic infection. Interferon alfa may convert hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) to an inactive carrier state, but prediction of sustained response is unsatisfactory. The aim of this study was to test the hypothesis that quantification of MHBs and LHBs may allow for a better prognosis of therapeutic response than total hepatitis B surface antigen (HBsAg) concentration. Methods: Hepatitis B surface proteins were measured before and during peginterferon alfa-2a therapy in serum from 127 Asian patients with HBeAg-positive CHB. Sustained response was defined as HBeAg seroconversion 24 weeks post-treatment.Results: Mean total HBs levels were significantly lower in responders vs nonresponders at all time points (P < .05) and decreased steadily during the initial 24 weeks treatment (by 1.16 vs 0.86 ng/mL in responders/nonresponders respectively) with unchanged relative proportions. Genotype B had a two-fold higher proportion of LHBs than genotype C (13% vs 6%). HBV DNA, HBeAg, HBsAg and HBs protein levels predicted response equally well but not optimally (area under the receiver operating characteristic curve values >0.70). Conclusions:Hepatitis B surface protein levels differ by HBV genotype. However, quantification of HBs proteins has no advantage over the already established HBsAg assays to predict response to peginterferon alfa-2a therapy in HBeAg-positive patients. K E Y W O R D SHBs proteins, HBsAg, peginterferon alfa-2a, predictors of response, subviral particles | 325 RINKER Et al.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Quantitation of large, middle and small hepatitis B surface proteins in HBeAg‐positive patients treated with peginterferon alfa‐2a

Rinker

Bremer

Schröder

et al. 2019

Liver International

View full text Add to dashboard Cite

show abstract

“…Many studies have reported that parameters such as alanine aminotransferase (ALT), HBsAg, HBeAg, antibody to hepatitis B core antigen (anti‐HBc), HBV‐DNA, and viral genotypes alone or in combination play a role in predicting HBeAg seroconversion in patients with HBeAg‐positive CHB receiving IFN or PEG‐IFN therapy . However, these studies typically focused on the performance of single parameters for predicting HBeAg seroconversion, while more complicated models with multiple parameters are of limited clinical value …”

Section: Introductionmentioning

confidence: 99%

Prediction model for sustained hepatitis B e antigen seroconversion to peginterferon alfa‐2a in chronic hepatitis B

Zhu

Wang

Zhang

et al. 2016

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…Positive HBeAg in serum indicates that HBV is actively replicating and highly infectious [ 18 , 19 ]. We found that fecal HBV DNA in patients with positive HBeAg was higher than in patients with negative HBeAg, and stool HBV DNA and serum HBV DNA were positively correlated.…”

Section: Discussionmentioning

confidence: 99%

Stool vs. Serum Hepatitis B Virus DNA in Patients with Chronic Hepatitis B

JiShun

Chen²,

Yang³

et al. 2015

Med Sci Monit

View full text Add to dashboard Cite

BackgroundSerum hepatitis B virus (HBV) DNA and hepatitis B e antigen (HBeAg) liver function in patients with chronic hepatitis B (CHB) are significantly associated. A comparison of clinical significance of fecal HBV DNA and serum HBV DNA has not yet been reported.Material/MethodsStool and serum samples were collected from 66 patients with CHB. Fecal HBV DNA, serum HBV DNA, and intestinal microbiota DNA were detected by real-time quantitative fluorescence polymerase chain reaction (PCR). Liver function and HBeAg were analyzed.ResultsThe stool and serum HBV DNA were positively correlated (r=0.57, P=0.001). Fecal HBV DNA was higher in the HBeAg-positive group than in the HBeAg-negative group (P=0.02). Fecal HBV DNA was negatively correlated with alkaline phosphatase (ALP) (r=−0.41, P=0.001) and TBIL (r=−0.29, P=0.02), and was positively correlated with Enterococcus (r=0.38, P=0.002). Serum HBV DNA was negatively correlated with alanine aminotransferase (ALT) (r=−0.30, P=0.02), aminotransferase (AST) (r=−0.26, P=0.049), and Lactobacillus (r=−0.31, P=0.01).ConclusionsThese observations suggest that fecal HBV DNA and serum HBV DNA in patients with CHB have different effects. Fecal HBV DNA might be associated with changes in Enterococcus concentrations, but serum HBV DNA is not.

show abstract

Early serum hepatitis B virus large surface protein level: A stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B

Cited by 15 publications

References 19 publications

Quantitation of large, middle and small hepatitis B surface proteins in HBeAg‐positive patients treated with peginterferon alfa‐2a

Quantitation of large, middle and small hepatitis B surface proteins in HBeAg‐positive patients treated with peginterferon alfa‐2a

Prediction model for sustained hepatitis B e antigen seroconversion to peginterferon alfa‐2a in chronic hepatitis B

Stool vs. Serum Hepatitis B Virus DNA in Patients with Chronic Hepatitis B

Contact Info

Product

Resources

About